Even if 2 to 4 billion NK cells are injected, only 10 to 20% reach cancer cells on average. The reason is that, before reaching the cancer cells, it is dispersed into bad blood and other diseases in the blood, and it has a therapeutic effect. NKCL has developed technology to reach up to 70% or more of NK cells in certain cancers for therapeutic purposes. It only maximizes the therapeutic effect by intensively attacking only cancer cells that cause life problems.